Amantadine HCl (3 mg kg-') was administered orally to 20 young healthy adults.
Introduction Methods
Amantadine, an aliphatic tricyclic primary amine (pKa = 10.1), is excreted predominantly unchanged into the urine and undergoes limited metabolism in man [1] . Nicotine, the major pharmacologically active component of tobacco smoke, is a weak organic cation (pKa = 7.9) [2] . At concentrations equivalent to those in the plasma of chronic smokers, nicotine, and its major metabolite, cotinine, increase amantadine accumulation in rat isolated renal proximal tubules [3] . The transport affinity for amantadine in rat renal distal tubules is lower in females than males [4] . In man, quinine and quinidine inhibit the renal clearance of amantadine only in males [5] . We assessed the influence of cigarette smoking on amantadine pharmacokinetics in humans as an extension of our in vitro studies in rats [3] . We tested the hypothesis that there is a gender-associated difference in amantadine renal clearance in humans by analyzing data from the present study combined with similar data from a previous study in a separate group of healthy men and women [5] .
Study design and drug analysis
A non-randomised parallel-group study was completed in 20 healthy male and female volunteers, balanced for gender and smoking status (five subjects/ group). Amantadine HCI concentrations in plasma and urine were assayed in duplicate by gas chromatographDr [6] . The lower assay limit in urine was 50 ng ml-and standard curves ranged from 130 to 1000 ng ml-' (r2 > 0.99, coefficient of variation = 5.5%). The lower assay limit in plasma was 10 ng ml-' and standard curves ranged from 50 to 800 ng ml-' (r2 > 0.99, coefficient of variation = 7.0%). [7] . Most comparisons were made with a two-way ANOVA model accounting for patient gender, smoking status, and gender by smoking-status interaction. To improve the statistical power of the gender comparisons, the 0-8 h amantadine CLR values (n = 20) were combined with corresponding data from other healthy subjects (n = 18) who participated in a separate study [5] . All data are reported as mean ± s.d. or median and (range). Mean differences and 95% confidence intervals of differences (CI) of selected parameters were calculated [8] .
Results
Demographic characteristics of the subjects are shown in Table 1 . Mean body weights and heights were higher in males than females (P < 0.001 and P < 0.012, respectively). Body surface area was higher in males than females (P < 0.004), but mean BMI values were comparable amongst the groups. Amantadine dosage adjusted for body weight or surface area was similar amongst the groups, whereas when adjusted for BMI it was greater in male than female subjects (P < 0.005). ;r' BMI), was greater in chronic smokers than non-smokers (P < 0.011).
Plasma amantadine concentrations from 2 to 24 h were lower in smokers, but this difference was not reflected in AUC data (mean difference ± 95% CI, 1.50 ± 3.27 mg 21 h). Cmax and tmax values were similar in smokers and non-smokers (565 ± 125 vs 620 ± 93 ng ml-' and 1.75 (1.5-6) h vs 2.5 (1-8) h, respectively).
Renal clearance was similar throughout the 0-6, 6-12, 12-24, 24-32, and 32-48 h collection periods (P > 0.087 for weight-, P > 0.115 for surface area-, and P > 0.116 for BMI-normalisation) (Figure 1 ). Urinary drug recovery at 48 h (mean difference + 95% CI, 0.132 ± 0.111) and CLR/CL ratios (mean difference ± 95% CI, 0.173 ± 0.148) were higher in male than female subjects irrespective of their smoking status (P < 0.032 in both cases). Both 0-8 h and total CLR values normalised for BMI showed gender-related differences (n = 20; P < 0.032 and P < 0.013 respectively). When the present weightcorrected 0-8 h CLR data were combined with corresponding data from a previous study [5] , data for both genders were consistent between the studies.
The mean CLR in male subjects (0.160 ± 0.075 1 kg-' h-1) was approximately 1.5-fold greater than in females (0.102 ± 0.053 1 kg-' h-1) (mean difference + 95% CI, 0.058 ± 0.057; P < 0.01; n = 38).
Discussion
The pharmacokinetic parameters of amantadine normalised for body weight were consistent with previous reports [1, 5] . Also, we have shown that the renal clearance of amantadine is time invariant. In contrast to our previous findings with rat renal tubules that nicotine and cotinine increase the renal tubular uptake of amantadine [4], we showed no effect of chronic smoking on the renal clearance of amantadine in man. There may be differences in CL and CLR between female smokers and abstainers. A statistical power calculation with a = 0.05 and b = 0.20 indicated a minimum sample size of 10 female subjects/ group to demonstrate a difference.
Conversely, the higher VzIF in smokers than nonsmokers was independent of gender. It is unlikely that such a difference is explained by variation in absorption, as 0-48 h urinary amantadine recoveries were similar in the two groups. Substantial amantadine sequestration has been demonstrated in the kidney, where a tissue to blood ratio of 29 was found 1 h after a 1.6 mg kg-' dose to mice [9] . The differences in VzIF may be attributed to a nicotine/cotinineinduced increase in renal amantadine uptake.
The finding of a higher renal clearance of amantadine in male than female subjects confirmed a previous observation [5] . The direction and magnitude were similar when renal clearance was normalised by three measures, indicating that variation in subject surface area and adiposity do not contribute to the gender effect. In the study of Gaudry et al. [5] a power calculation with a = 0.05 and b = 0.20, indicated that 28 subjects would be required to demonstrate a gender difference in the renal clearance of amantadine. Combination of relevant data from both studies (n = 38) satisfied the sample size requirement for body weight-normalised CLR data [5] . Together, these data provide evidence in support of the hypothesis that gender differences in renal organic cation handling observed in the rat apply also to humans.
In conclusion, our results support a pharmacokinetic explanation for a reported higher occurrence of adverse events associated with therapeutic amantadine doses in female compared with male subjects [10] , since a lower renal clearance of amantadine would predict a greater body burden at steady-state.
